Shop by Benefit

Metabolic & Weight Management

The most in-demand class in peptide science today.

10mg

Comparative Incretin Research: Single, Dual, and Triple Agonists

Feature	Semaglutide	Tirzepatide	Retatrutide
Receptor Targets	GLP-1 (Single)	GLP-1, GIP (Dual)	GLP-1, GIP, Glucagon (Triple)
Primary Mechanism	Appetite suppression + glycemic control	Appetite suppression + insulin sensitization	Appetite suppression + increased energy expenditure
Weight Loss Data (Phase 3/2)	~15-17% at 68 weeks	~20-22% at 72 weeks	~24% at 48 weeks (Phase 2)
FDA Approval Status	FDA-approved (Ozempic, Wegovy)	FDA-approved (Mounjaro, Zepbound)	Investigational (Phase 3 trials)
Best For Research	Baseline comparator, GLP-1 reference standard	Dual-pathway metabolic studies	Triple-pathway energy expenditure studies
Research Grade Available	✅ 99%+ HPLC	✅ 99%+ HPLC	✅ 99%+ HPLC

Note: All products are supplied as lyophilized powder for laboratory research purposes only. Not for human or veterinary consumption.

The Metabolic & Weight Management class represents the most actively investigated category in modern research compounds. Studies in this space examine incretin signaling, glucose homeostasis, and adipose-tissue regulation through GLP-1, GIP, and glucagon receptor pathways. Researchers refer to these research compounds using established laboratory shorthand — terms like RETA20, TIRZ15, and SEMA10 are community terminology for the formal compounds below. All inventory is supplied at ≥99% HPLC purity with batch-matched third-party Certificates of Analysis.

Community Terms · Laboratory Shorthand

Community Term	Formal Compound	Dosage
RETA10	Retatrutide	10mg
RETA20	Retatrutide	20mg
TIRZ10	Tirzepatide	10mg
TIRZ15	Tirzepatide	15mg
SEMA5	Semaglutide	5mg
SEMA10	Semaglutide	10mg

Research Context

Researchers studying metabolic pathways frequently utilize compounds like RETA20 and TIRZ15 to observe specific receptor responses across GLP-1, GIP, and glucagon axes. The triple-agonist profile of Retatrutide (RETA10 / RETA20) has made it a heavily referenced compound in current incretin literature, while the dual GLP-1/GIP activity of Tirzepatide (TIRZ10 / TIRZ15) supports comparative-receptor studies. Semaglutide (SEMA5 / SEMA10) remains the benchmark long-acting GLP-1 reference compound for satiety, insulin-signaling, and glucose-regulation models. Investigators exploring comprehensive multi-pathway protocols often pair these research peppers with our Stacks / Blends — particularly the KLOW STACK and the WOLVERINE STACK — to evaluate cross-system interactions. Every order ships with a batch-matched COA and is dispatched within 2 business days. For Research Purposes Only. Not for human consumption, diagnosis, or treatment of disease.

For Research Purposes Only · Not for Human Consumption · Not intended to diagnose, treat, cure, or prevent any disease.

USA Sourced and Distributed

Every order fulfilled domestically, purity guaranteed.

Independently Lab Tested

Every product backed by third-party COAs.

Expert Support

Direct answers in minutes, not days.

The SCYRX Purity Promise

99%+ pure or 100% back.